Cypherpunk Technologies Inc. - CYPH

Cypherpunk Technologies Inc. is a biopharmaceutical company focused on developing novel antibody therapies for cancer treatment, with a strategic emphasis on biomarker-targeted approaches. The company’s lead clinical-stage candidate, DKN-01, is a monoclonal antibody designed to inhibit Dickkopf-related protein 1 and is currently being evaluated in multiple clinical trials for esophagogastric, gynecologic, and colorectal cancers. Additional pipeline assets include FL-301, targeting Claudin18.2-expressing cells, and preclinical programs FL-302 and FL-501. Cypherpunk Technologies also distinguishes itself with a unique digital asset treasury strategy, actively acquiring and holding Zcash (ZEC) as part of its long-term value-building initiative. The company’s research and development operations are conducted through its wholly-owned subsidiary, Leap Therapeutics, Inc. Headquartered in Cambridge, Massachusetts, Cypherpunk Technologies operates at the intersection of biotechnology innovation and digital asset investment, reflecting its dual commitment to advancing cancer therapies and supporting privacy-focused technologies.